IDH1 and glioblastoma: The patient received ReRT at a dose of 60 Gy in 30 fractions combined with TMZ; however, the patient had a distant recurrence in the cerebellum 23.0 months after the treatment for GBM with IDH1/2 wild-type (Fig. 3E) and died 12.1 months thereafter.